ZVRA Earnings Date: Nov 3, 2026 (Estimated) — Zevra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ZVRA's next earnings date?
Zevra Therapeutics, Inc. (ZVRA) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.14 on revenue of $37.1M.
How did ZVRA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Zevra Therapeutics, Inc. posted EPS of $0.25 versus the $0.11 estimate, a beat of 78.6%. Revenue was $39.7M against a $33.9M estimate. The stock's 1-day post-earnings move was +12.8%.
How much does ZVRA stock move after earnings?
ZVRA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.0% (up or down) in the day after earnings.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.11 | 0.25 | +78.57% | $39.7M | ✅ Beat | +12.82% | +8.64% | +19.09% |
| 2026-05-06 | Q1 2026 | 0.08 | 0.18 | +125.00% | $36.2M | ✅ Beat | -2.22% | -1.16% | -5.69% |
| 2026-03-09 | Q4 2025 | 0.05 | 0.19 | +280.00% | $34.1M | ✅ Beat | +21.27% | +8.22% | +5.15% |
| 2025-11-05 | Q3 2025 | -0.03 | -0.01 | +66.67% | $26.1M | ✅ Beat | -9.73% | -6.65% | -13.51% |
| 2025-08-12 | Q2 2025 | 1.40 | 1.24 | -11.43% | $25.9M | ❌ Miss | -19.81% | -23.43% | -32.40% |
| 2025-03-11 | Q4 2024 | -0.40 | -0.67 | -67.50% | $12.0M | ❌ Miss | -1.86% | -1.24% | -15.12% |
| 2024-11-12 | Q3 2024 | -0.42 | -0.69 | -64.29% | $3.7M | ❌ Miss | +1.05% | +4.67% | -1.52% |
| 2024-08-13 | Q2 2024 | -0.44 | -0.48 | -9.09% | $4.4M | ❌ Miss | +3.10% | +11.95% | +11.95% |
Showing last 8 quarters.